A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Bertero, Thomas ^a,e   Cottrill, Katherine A ^a   Annis, Sofia ^a   Bhat, Balkrishen ^b,f   Gochuico, Bernadette R ^c   Osorio, Juan C ^a   Rosas, Ivan ^a   Haley, Kathleen J ^a   Corey, Kathleen E ^d   Chung, Raymond T ^d   Nelson Chau, B ^b,f   Chan, Stephen Y ^a,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b REGULUS THERAPEUTICS   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^f Translate Bio Inc   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; APOLIPOPROTEIN E; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 8; MICRORNA; MIRN130 MICRORNA, HUMAN; MIRN301 MICRORNA, HUMAN; PHOSPHOPROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; WWTR1 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL; DISEASE MODEL; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; LIVER CIRRHOSIS; LUNG FIBROSIS; METABOLISM; MOUSE; PATHOLOGY; PULMONARY HYPERTENSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOLIPOPROTEINS E; BENZOATES; BENZYLAMINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; HYPERTENSION, PULMONARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LDL-RECEPTOR RELATED PROTEINS; LIVER CIRRHOSIS; MICE; MICRORNAS; PHOSPHOPROTEINS; PULMONARY FIBROSIS;

EID: 84950246154     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18277     Document Type: Article

References (63)

1. Butcher, D. T., Alliston, T. & Weaver, V. M. A tense situation: Forcing tumour progression. Nat Rev Cancer. 9, 108-122 (2009).
2. Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 196, 395-406 (2012).
3. Dupont, S. et al. Role of yap/taz in mechanotransduction. Nature. 474, 179-183 (2011).
4. Cordenonsi, M. et al. The hippo transducer taz confers cancer stem cell-related traits on breast cancer cells. Cell. 147, 759-772 (2011).
5. Harvey, K. F., Zhang, X. & Thomas, D. M. The hippo pathway and human cancer. Nat Rev Cancer. 13, 246-257 (2013).
6. Pan, D. The hippo signaling pathway in development and cancer. Dev Cell. 19, 491-505 (2010).
7. Fujii, M. et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 209, 479-494 (2012).
8. Liu, F. et al. Mechanosignaling through yap and taz drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 308, L344-357 (2015).
9. Bertero, T. et al. Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the Yap/TazmiR-130/301 circuit Cell Reports. 13, 1016-1032 (2015).
10. Valastyan, S. & Weinberg, R. A. Roles for micrornas in the regulation of cell adhesion molecules. J Cell Sci. 124, 999-1006 (2011).
11. Parikh, V. N. et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: Results of a network bioinformatics approach. Circulation. 125, 1520-1532 (2012).
12. Bertero, T. et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest. 124, 3514-3528 (2014).
13. Pencheva, N., Buss, C. G., Posada, J., Merghoub, T. & Tavazoie, S. F. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell. 156, 986-1001 (2014).
14. Chan, S. Y. & Loscalzo, J. The emerging paradigm of network medicine in the study of human disease. Circ Res. 111, 359-374 (2012).
15. Goh, K. I. et al. The human disease network. Proc Natl Acad Sci USA. 104, 8685-8690 (2007).
16. Zhou, X., Menche, J., Barabasi, A. L. & Sharma, A. Human symptoms-disease network. Nat Commun. 5, 4212 (2014).
17. Bitanihirwe, B. K. & Woo, T. U. Perineuronal nets and schizophrenia: The importance of neuronal coatings. Neurosci Biobehav Rev. 45C, 85-99 (2014).
18. Michalik, L. & Wahli, W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 116, 598-606 (2006).
19. Lakatos, H. F. et al. The role of ppars in lung fibrosis. PPAR Res. 2007, 71323 (2007).
20. Wang, Z. et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobil Pancr Dis Int. 10, 64-71 (2011).
21. Kampschulte, M. et al. Western diet in apoe-ldlr double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis. Lab Invest. 94, 1273-1282 (2014).
22. Ferre, N. et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic apoe-deficient mice: Potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol. 296, G553-562 (2009).
23. Kothapalli, D. et al. Cardiovascular protection by apoe and apoe-hdl linked to suppression of ecm gene expression and arterial stiffening. Cell Rep. 2, 1259-1271 (2012).
24. Gressner, O. A. & Gressner, A. M. Connective tissue growth factor: A fibrogenic master switch in fibrotic liver diseases. Liver Int. 28, 1065-1079 (2008).
25. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 139, 891-906 (2009).
26. Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 16, 1009-1017 (2010).
27. Nave, A. H. et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterio Thromb Vasc Biol. 34, 1446-1458 (2014).
28. Calvo, F. et al. Mechanotransduction and yap-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 15, 637-646 (2013).
29. Piccolo, S., Dupont, S. & Cordenonsi, M. The biology of yap/taz: Hippo signaling and beyond. Physiol Rev. 94, 1287-1312 (2014).
30. Plouffe, S. W., Hong, A. W. & Guan, K. L. Disease implications of the hippo/yap pathway. Trends Mol Med. 21, 212-222 (2015).
31. Liu, A. M., Xu, M. Z., Chen, J., Poon, R. T. & Luk, J. M. Targeting yap and hippo signaling pathway in liver cancer. Ex Opin Ther Targ. 14, 855-868 (2010).
32. Pottier, N. et al. Identification of keratinocyte growth factor as a target of microrna-155 in lung fibroblasts: Implication in epithelialmesenchymal interactions. PLoS One. 4, e6718 (2009).
33. Pandit, K. V. et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 182, 220-229 (2010).
34. van Rooij, E. et al. Dysregulation of micrornas after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 105, 13027-13032 (2008).
35. Xiao, J. et al. Mir-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther. 20, 1251-1260 (2012).
36. Roderburg, C. et al. Micro-RNA profiling reveals a role for mir-29 in human and murine liver fibrosis. Hepatology. 53, 209-218 (2011).
37. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating map kinase signalling in fibroblasts. Nature. 456, 980-984 (2008).
38. Liu, G. et al. MiR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 207, 1589-1597 (2010).
39. Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 4, 121-118 (2012).
40. da Costa Martins, P. A. et al. Microrna-199b targets the nuclear kinase dyrk1a in an auto-amplification loop promoting calcineurin/nfat signalling. Nat Cell Biol. 12, 1220-1227 (2010).
41. Lino Cardenas, C. L. et al. Mir-199a-5p is upregulated during fibrogenic response to tissue injury and mediates tgfbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 9, e1003291 (2013).
42. Chou, J. et al. Gata3 suppresses metastasis and modulates the tumour microenvironment by regulating microrna-29b expression. Nat Cell Biol. 15, 201-213 (2013).
43. Mouw, J. K. et al. Tissue mechanics modulate microrna-dependent pten expression to regulate malignant progression. Nat Med. 20, 360-367 (2014).
44. Tumaneng, K. et al. Yap mediates crosstalk between the hippo and pi(3)k-tor pathways by suppressing pten via mir-29. Nat Cell Biol. 14, 1322-1329 (2012).
45. Jiang, J. et al. Association of microrna expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 14, 419-427 (2008).
46. Wang, W. Y. et al. High expression of microrna-130b correlates with poor prognosis of patients with hepatocellular carcinoma. Diagnostic pathology. 9, 160 (2014).
47. Shi, W. et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 71, 2926-2937 (2011).
48. Ma, F. et al. Upregulated microrna-301a in breast cancer promotes tumor metastasis by targeting pten and activating wnt/beta-catenin signaling. Gene. 535, 191-197 (2014).
49. Luo, H., Zhu, H., Zhou, B., Xiao, X. & Zuo, X. Microrna-130b regulates scleroderma fibrosis by targeting peroxisome proliferatoractivated receptor gamma. Mod Rheum.1-8 (2015).
50. Kim, K. M. et al. Shear stress induced by an interstitial level of slow flow increases the osteogenic differentiation of mesenchymal stem cells through taz activation. PLoS One. 9, e92427 (2014).
51. Johnson, R. & Halder, G. The two faces of hippo: Targeting the hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 13, 63-79 (2014).
52. Bertero, T. et al. The microrna-130/301 family controls vasoconstriction in pulmonary hypertension. J Biol Chem. 290, 2069-2085 (2014).
53. Brock, M. et al. The hypoxia-induced microrna-130a controls pulmonary smooth muscle cell proliferation by directly targeting cdkn1a. Int J Biochem Cell Biol. 61C, 129-137 (2015).
54. Simonneau, G. et al. Updated clinical classification of pulmonary hypertension. JJ Am Coll Cardiol. 62, D34-41 (2013).
55. Kramann, R. et al. Perivascular gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 16, 51-66 (2014).
56. Wei, C. et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One. 8, e64396 (2013).
57. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science. 295, 2387-2392 (2002).
58. Hu, J., Van den Steen, P. E., Sang, Q. X. & Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 6, 480-498 (2007).
59. Obad, S. et al. Silencing of microrna families by seed-targeting tiny lnas. Nat Genet. 43, 371-378 (2011).
60. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell. 120, 15-20 (2005).
61. El-Chemaly, S. et al. Glucose transporter-1 distribution in fibrotic lung disease: Association with [(1)(8)f]-2-fluoro-2-deoxyglucosepet scan uptake, inflammation, and neovascularization. Chest. 143, 1685-1691 (2013).
62. Corey, K. E. et al. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 10, 651-656 (2012).
63. Corey, K. E. et al. The absence of obstructive sleep apnea may protect against non-alcoholic fatty liver in patients undergoing bariatric surgery. PLoS One. 8, e62504 (2013).